2 7:: :56 75<2 )=< :**6 - - PDF document

7/7/2015 1

• !"#
• $ %&

$ '

• $ ( ))*

+ +,

• $ + -"
• $

++"

Lee, JASN 18: 1936-41, 2007

(#,.)

$ /+

0+

• !

1

• 2

34#1)5)678'9):**;

• :**6

7:: :56 75<2 )=< 3>:*)7 )*): ):5 9*<2 )6< 1

• 4#1958'6::**6

3>4#155)*'5)5:*)7 2?***)

7/7/2015 2

• 2

34#1)5)678'9):**;

!" #$

$ >)=9

• 9:<,@)

$ 3);7

• 99<,@)

$ -:567)*

• =*<,@)
• )5<,@)

>4A();5*;'5)7:**8 34#18=;='=5):*))

• :*)=1B""
• $ :599*-:**5

$ ;;<+ $ C"+ " :)<+' 6* $ C"+ "=9<+' 6*

Lacson et al, 2009 ASN free communication

(#,.:

$ D 3" ! 3" 1

D #

Saran, NDT 19: 2334-2340, 2004 "

DOPPS: 2% cannulated within 1 month.

Saran, NDT 19: 2334-2340, 2004

D #

Weeks after AVG surgery

DOPPS: 78% cannulated within 1 month.

7/7/2015 3

• !"#"$"

2

34#1)5)678'9):**;

(>+ '

%&' 77=< 8=9< ) ;6<

()*+,-'.,/00-),1.2

N=472

• %
• &'$$

2

34#1)5)678'9):**;

C !EC(ED(DAC1

AVF AVG p-value N patients 59 51 Primary failures 44% 20% 0.006

• Interv. before maturation 0.42

0.16 0.04 Catheter dependence (days) 131 34 <0.001 #CRB before maturation 1.33 0.38 0.003

Lee, JASN 18: 1936-41, 2007

! "#$

( ()

• *"$$

2

34#1)5)678'9):**;

(#,.7

$ A /'' 3" ! 3" 1

7/7/2015 4

Excluding primary failures Including primary failures Maya, CJASN 4: 86-92, 2009 322 289

Lok, CJASN 8:810-818, 2013

Including primary failures Excluding primary failures

1012 AVF 128 AVG

Schild, J Vasc Acc 9:231-235, 2008 Including primary failures 998 AVF 702 AVG

0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 Palder 1985 Coburn 1994 Rocco 1996 Miller 1997 Hodges 1997 Gibson 2001 Oliver 2001 Allon 2001 Dixon 2002

Cumulative survival at 1 year (Graft/fistula) 4#1:;58'5**:**;

( !

(#,.9

$ F ,

, G

! 1

• %

) %

• $$#

2

34#1)5)678'9):**;

7/7/2015 5

1 2 3 4 5 6 7 8 Winsett 1985 Rocco 1996 Miller 1997 Hodges 1997 Gibson 2001 Oliver 2001 Allon 2001 McCarley 2001 Dixon 2002

Revision rate per access-year (Graft/fistula) 4#1:;58'5**:**;

,

C DE(D(DAC1

AVF AVG p-value N patients 59 51 Median survival in days (excluding prim failures) 1524 517 0.03

• Interv. per year after

access maturation 0.73 2.38 <0.001

Lee, JASN 18: 1936-41, 2007

&

• '

,

• Lee, CJASN 6: 575-581, 2011

Median surv 2 years: Same as AVG! Excluding primary failures

,

• +H

Harms, NKF spring clinical meeting poster

I

" " 3

$ 3

• ,
• * *;8J
• ) )7;J
• @: 7=)J

$ -

• ,
• * *98J
• @) *59J

34#18=;='=5):*))

• :*)=1B""

7/7/2015 6

43)

• '
• $ /'

$ + $ ,+

• $ K

$ %&>

• '
• $ 2

$ ,

$ D""BCLA

"

2A "H

(%)*+

• "$
• ,

7/7/2015 7

• "++%

GGG

"H

5 # 6

• )668'65

M7=* 95 :**9'*5 M=** ): D+ ! ;=<@9*<-H 4B7885';9:*** #"4B=5:97';:*))

#=*< "G & )7819 3

:

• $

$ D +M=*<

=*<

$ "M=*<+

+

• $ # +"

"-

• $ AK"H